ABL Bio Announces Additional Clinical Data for ABL111 and ABL503, Pushes Ahead with Follow-on Development
Predicted impact: Low
ESMO clinical data presentation already announced in the last 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.